Genomic Sequencing Investigation of 733 HER2-amplified Most important and metastatic breast tumours discovered important enrichment of mutations that activate RAS–MAPK signalling in Sophisticated tumours dealt with with prior anti-HER2 therapies121. These mutations, which includes NF1 and HER2 activating mutations, add to resistance to tucatinib and neratinib. Triple-adverse breast ca... https://www.directivepublications.org/journal-of-clinical-breast-cancer/